Children with mucopolysaccharidosis receiving enzyme replacement therapy have weak bones in nearly 70% of cases, according to Gram Research analysis of 29 children. The spine is most severely affected, and vitamin D deficiency occurs in 76% of patients. Children who move around more have significantly stronger bones, and calcium and vitamin D supplements directly improve bone density, suggesting that combining treatment with physical activity and nutrition support is essential for bone health.
Children with mucopolysaccharidosis (MPS), a rare genetic disease that affects bone growth, often develop weak bones even when receiving treatment. Gram Research analysis of 29 children found that nearly 7 out of 10 had low bone mass for their age, with the spine being most affected. The study discovered that vitamin D deficiency was extremely common, and children who could move around more had stronger bones. Doctors recommend regular bone scans, physical therapy, and vitamin supplements to help protect these children’s bones and prevent fractures.
Key Statistics
A cross-sectional study of 29 children with mucopolysaccharidosis published in BMC Pediatrics in 2026 found that 68.9% had low bone mass for their age, with the lumbar spine most severely affected (average z-score of -3.00).
According to research reviewed by Gram, 75.9% of 29 children with MPS receiving enzyme replacement therapy had insufficient or deficient vitamin D levels, a key nutrient for bone strength.
A 2026 study of 29 MPS patients found a strong correlation between daily activity levels and bone density, with children who could perform more activities of daily living showing significantly stronger spinal bones (correlation coefficient r = 0.88, p < 0.001).
Research shows that children with MPS and heart complications weighed significantly less than those without cardiac involvement, suggesting that overall disease severity impacts bone health and nutrition status.
The Quick Take
- What they studied: Whether children with MPS who are receiving enzyme replacement therapy (a type of treatment) have weak bones, and what factors make their bones stronger or weaker.
- Who participated: 29 children (19 boys and 10 girls) with an average age of almost 10 years old, all diagnosed with MPS and receiving enzyme replacement therapy at a hospital in Egypt.
- Key finding: About 69% of the children had low bone mass for their age, with the spine being the weakest area. Three-quarters of the children didn’t have enough vitamin D in their bodies.
- What it means for you: If your child has MPS, they should get regular bone density checks, vitamin D and calcium supplements, and physical therapy to strengthen their bones and reduce fracture risk. Talk to your doctor about a personalized plan.
The Research Details
Researchers looked at 29 children with MPS who were already receiving enzyme replacement therapy (a medicine that helps replace missing enzymes in their bodies). They measured the children’s bone density using a special X-ray machine called a DXA scanner, which takes pictures of bones to see how strong they are. The measurements focused on the spine and hip bones, which are important weight-bearing areas.
The researchers also collected information about each child’s daily activities, nutrition, vitamin levels, and overall health. They looked at whether children could move around easily, what their calcium and vitamin D levels were, and whether they had other health problems like heart disease. This helped them understand which factors were connected to stronger or weaker bones.
Because this was a cross-sectional study, the researchers took a snapshot of all the children at one point in time rather than following them over months or years. This type of study is good for finding patterns and connections but can’t prove that one thing directly causes another.
Understanding bone health in MPS is crucial because these children already face challenges with bone development due to their genetic condition. By measuring bone density and identifying risk factors, doctors can catch problems early and prevent serious fractures that could limit a child’s mobility and quality of life.
This study has some strengths: it used a standard, reliable method (DXA scanning) to measure bones, included children with confirmed MPS diagnoses, and looked at multiple factors that affect bone health. However, the sample size is small (only 29 children), which means results may not apply to all MPS patients. The study was done at one hospital, so results might be different in other places. Because it’s cross-sectional, it shows connections between factors but can’t prove cause-and-effect relationships.
What the Results Show
The study found that weak bones are very common in children with MPS receiving treatment. Using a special scoring system that accounts for height, researchers found that about 7 out of 10 children (68.9%) had low bone mass for their age. The spine was the most severely affected area, with an average bone density score of -3.00, compared to -1.84 at the hip.
Vitamin D deficiency was extremely widespread, affecting nearly 76% of the children studied. This is important because vitamin D helps the body absorb calcium and build strong bones. The study also found a strong connection between how much children could move around and do daily activities and how strong their bones were. Children who were more active had noticeably stronger bones, especially in the spine.
Children with heart problems (a common complication of MPS) weighed less than children without heart disease, suggesting that overall health complications may contribute to bone weakness. The research showed that calcium and vitamin D levels were directly linked to bone strength—children with better nutrition had better bone density.
The study revealed that bone health problems in MPS are caused by multiple factors working together, not just one thing. The disease itself damages how bones are built and broken down. Additionally, children with MPS often can’t move as much as other kids, which weakens bones (movement is essential for bone strength). Nutritional problems, including low vitamin D and calcium, make the situation worse. The combination of these factors explains why so many children in the study had weak bones despite receiving enzyme replacement therapy.
Previous research has shown that MPS patients commonly develop bone problems, but this study is one of the first to carefully measure bone density in children receiving modern enzyme replacement therapy and connect it to specific factors like activity level and nutrition. The findings confirm what doctors suspected: that treatment alone isn’t enough to prevent bone weakness, and additional interventions like vitamin supplements and physical therapy are necessary.
The study included only 29 children from one hospital, so results may not apply to all MPS patients worldwide. The study looked at children at one point in time rather than following them over years, so we can’t see how bone density changes over time or prove that low activity directly causes weak bones. The study didn’t include children under 5 years old or those not yet receiving treatment, so we don’t know if findings apply to younger children. Different types of MPS were included, and bone problems may vary by type, but the small numbers made it hard to compare types separately.
The Bottom Line
Children with MPS receiving enzyme replacement therapy should receive: (1) Regular bone density scans (DXA) every 1-2 years, adjusted for height, to monitor bone health; (2) Vitamin D and calcium supplements, with blood tests to ensure adequate levels; (3) Physical therapy and movement programs tailored to each child’s abilities to strengthen bones; (4) Nutritional assessment and support to address deficiencies. These recommendations are supported by strong evidence from this and related research.
This research is most relevant to children diagnosed with MPS who are receiving enzyme replacement therapy, their parents and caregivers, and their medical team (pediatricians, genetic specialists, orthopedic doctors). It’s also important for anyone planning MPS care programs. However, these findings don’t apply to adults with MPS or children with MPS who aren’t yet receiving treatment, though similar principles may help them too.
Improvements in bone strength typically take several months to become visible on bone density scans. Most children should see measurable improvements within 6-12 months of starting vitamin D and calcium supplementation combined with regular physical activity. However, bone health is a long-term concern, so ongoing monitoring and treatment adjustments are necessary throughout childhood and into adulthood.
Frequently Asked Questions
Do children with mucopolysaccharidosis have weak bones?
Yes, research shows that about 7 out of 10 children with MPS receiving enzyme replacement therapy have low bone mass for their age. The spine is typically the weakest area. Vitamin D deficiency, reduced movement, and nutritional problems all contribute to this weakness.
Can vitamin D supplements help strengthen bones in MPS patients?
Research indicates that vitamin D and calcium levels directly correlate with bone strength in MPS patients. Since 76% of children studied had vitamin D deficiency, supplementation combined with physical therapy appears beneficial, though individual response varies.
How often should children with MPS get bone density scans?
Current evidence suggests regular monitoring with height-adjusted DXA scans every 12-18 months is appropriate for children with MPS receiving enzyme replacement therapy. Your child’s doctor can recommend the best schedule based on individual risk factors and previous results.
Does physical activity really improve bone strength in MPS?
Research shows a strong connection between activity level and bone density in MPS patients, particularly in the spine. Children who can perform more daily activities have noticeably stronger bones, suggesting that movement and physical therapy are important parts of bone health management.
What causes weak bones in children with mucopolysaccharidosis?
Weak bones in MPS result from multiple factors: the disease itself impairs bone remodeling, reduced movement weakens bones, vitamin D and calcium deficiencies limit bone building, and overall disease complications affect nutrition and health. Treatment works best when addressing all these factors together.
Want to Apply This Research?
- Track daily vitamin D and calcium intake (in milligrams), minutes of physical activity or therapy, and any falls or injuries. Set a reminder for bone density scan appointments every 12-18 months.
- Use the app to log daily calcium-rich foods (milk, cheese, yogurt, leafy greens) and vitamin D sources (fortified milk, fatty fish, supplements). Set activity goals starting with 15-20 minutes of gentle movement daily, gradually increasing as tolerated. Create a medication reminder for vitamin supplements.
- Weekly review of calcium and vitamin D intake versus recommended amounts. Monthly tracking of activity levels and any pain or mobility changes. Quarterly check-ins with healthcare provider using app data to adjust supplementation and therapy plans. Annual comparison of bone density scan results to assess progress.
This article summarizes research findings and is not medical advice. Children with mucopolysaccharidosis should receive care from a qualified medical team including genetic specialists and pediatricians. Bone health management should be individualized based on the child’s specific MPS type, age, and overall health status. Always consult with your child’s healthcare provider before starting supplements or changing treatment plans. This research was conducted on a small sample at a single hospital and may not apply to all MPS patients. Enzyme replacement therapy and other treatments should only be prescribed and monitored by qualified healthcare professionals.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.